BioPharma DiveOriginal article
Novartis says MS pill succeeds in two large studies
Data ReadoutpositiveremibrutinibPositive
AI Analysis
Summary
Novartis announced positive results from two large clinical studies of remibrutinib for multiple sclerosis, with notably improved liver safety profile compared to other BTK inhibitors in its class.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Two large studies succeeded; drug not associated with liver-related side effects seen with other BTK inhibitors
Importance:7/10
Sentiment:
0.75
MSBTK inhibitorclinical trialsafety profile
Related Companies
Read the original article
Published by BioPharma Dive on September 1, 2026 3:58 PM